Circulating tumor cells detection in tumor draining vein of breast cancer patients

Circulating tumor cells (CTCs) in tumor draining vein blood (DB) are potential sources for liquid biopsy. However, the identification of CTCs in DB of breast cancer has not been attempted. In this study, we investigated the feasibility of CTC detection in DB of breast cancer patients using a newly developed filtration-based microfluidic CTC detection device. Samples of peripheral vein blood (PB) and DB drawn from the lateral thoracic vein of the resected breast tissue were collected during the perioperative period. We investigated 41 breast cancer patients who underwent breast surgery with axillary lymph node dissection. DB was successfully collected in 36 patients (87.8%), with a mean amount of 0.85 ml. CTCs were detected in 58.3% of PB samples and 80.6% of DB samples. DB had significant higher number of CTCs compared with PB (p < 0.001). CTCs were detected in 75.0% of DB samples and 50.0% of PB samples from patients achieving pathological complete response after neoadjuvant chemotherapy. These results suggest that abundant CTCs are released into the DB of breast cancer patients, indicating that CTCs in DB would be alternative sources for liquid biopsy and potential indicators for monitoring of treatment response and prognosis in breast cancer patients.

[1]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[2]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.

[3]  H. Kuerer,et al.  Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I–III Triple-Negative Breast Cancer , 2015, Annals of Surgical Oncology.

[4]  S. Góźdź,et al.  Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors. , 2017, Translational research : the journal of laboratory and clinical medicine.

[5]  J. Wind,et al.  Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  Y. Kodera,et al.  Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models , 2017, Breast Cancer Research and Treatment.

[7]  Taisuke Masuda,et al.  Development of a New Rapid Isolation Device for Circulating Tumor Cells (CTCs) Using 3D Palladium Filter and Its Application for Genetic Analysis , 2014, PloS one.

[8]  F. Tanaka,et al.  Circulating tumor cells in pulmonary venous blood of primary lung cancer patients. , 2009, The Annals of thoracic surgery.

[9]  Y. Kodera,et al.  Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis , 2006, British Journal of Cancer.

[10]  H. Kuerer,et al.  Circulating tumour cells in non-metastatic breast cancer: a prospective study. , 2012, The Lancet. Oncology.

[11]  P. V. van Dam,et al.  Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes , 2013, British Journal of Cancer.

[12]  F. Schmidt.  Meta-Analysis , 2008 .

[13]  M. Koch,et al.  Compartmental Differences of Circulating Tumor Cells in Colorectal Cancer , 2012, Annals of Surgical Oncology.

[14]  P. Gullino,et al.  Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. , 1975, Cancer research.

[15]  K. Pantel,et al.  Characterization of single circulating tumor cells , 2017, FEBS letters.

[16]  N. Tsubota,et al.  Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. , 2013, Interactive cardiovascular and thoracic surgery.

[17]  Y. Yatabe,et al.  Detection of abundant megakaryocytes in pulmonary artery blood in lung cancer patients using a microfluidic platform. , 2018, Lung cancer.

[18]  Anne Vincent-Salomon,et al.  Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.

[19]  S. Sleijfer,et al.  Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  F. Bertucci,et al.  Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Büchler,et al.  Prognostic value of circulating endothelial cells in metastatic colorectal cancer , 2017, Oncotarget.

[23]  K. Pantel,et al.  Functional Studies on Viable Circulating Tumor Cells. , 2016, Clinical chemistry.

[24]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Campone,et al.  High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  R. Kimmig,et al.  Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy , 2016, Breast Cancer Research.

[27]  M. Campone,et al.  High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. , 2012 .

[28]  Michael P. MacManus,et al.  Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? , 2017, Nature Reviews Clinical Oncology.

[29]  Sridhar Ramaswamy,et al.  HER2 expression identifies dynamic functional states within circulating breast cancer cells , 2016, Nature.

[30]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[31]  Klaus Pantel,et al.  Liquid Biopsies, What We Do Not Know (Yet). , 2017, Cancer cell.

[32]  R W Raven,et al.  The british association of surgical oncology , 1973, Annals of the Royal College of Surgeons of England.

[33]  Xiaoyu Jia,et al.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. , 2009, The Lancet. Oncology.

[34]  S. Sleijfer,et al.  Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis , 2018, Journal of the National Cancer Institute.

[35]  T. Fehm,et al.  Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial , 2017, Clinical Cancer Research.

[36]  D. Beer,et al.  Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. , 2017, Cancer research.

[37]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.